Cholesterol Specialist Maryland
2024 NLA Expert Clinical Consensus on Apoprotein B (Apo B)
Here I summarize the National Lipid Association’s recent expert consensus, which emphasizes apolipoprotein B (Apo B) as a key tool in managing cardiovascular risk. Apo B, present on atherogenic lipoproteins, gives a more precise assessment of cardiovascular risk than traditional LDL cholesterol (LDL-C) measurements.
Published
Leqvio: A Breakthrough PCSK9 Inhibitor Using Gene Silencing to Lower LDL Cholesterol
Leqvio (Inclisiran) has received FDA approval as an additional therapy to diet and maximally tolerated statin medications for adults diagnosed with either heterozygous familial hypercholesterolemia (HeFH) or severe ASCVD who require further reduction of LDL cholesterol.
Published
Categorized as Dr. Tashko’s Key Clinical Trials, Drug Information, FDA Approvals, Heart Health, Lipid Health